Merck Says European Medicines Agency's Committee for Medicinal Products For Human Use Approves KEYTRUDA (pembrolizumab), Anti-PD-1 Therapy, In Combination With Pemetrexed And Platinum Chemotherapy, For Adult Patients With Unresectable Non-epithelioid Malignant Pleural Mesothelioma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Source:
    Benzinga.com. 2024.